Sandoz, a global generics company that is a significant part of the Novartis group, has unveiled a new drug targeted at managing heart failure and controlling blood pressure.
Novartris unveiled the ‘Candesartan Sandoz’ drug recently in Lagos, with the aim of allowing millions access affordable medications without compromising product quality at a much reduced cost.
Speaking at the launch, the Country Head, Novartis, Mr. Adepeju Idowu said: “We are introducing Candesartan Sandoz to address the unmet need in the management of cardiovascular disease particularly Hypertension, Left ventricular hypertrophy (LVH) and the Heart failure. Sandoz, as at today is the number two biggest generic business in the world worth more than $10 billion. And we are committed to bring out quality medications.”
He also added that treatment with Candesartan reduces mortality and hospitalisation due to heart failure and improves symptoms in patients with left ventricular systolic dysfunction.